CD79A Antibody (IGA/515) - Azide and BSA Free, Novus Biologicals™

CD79A

1.0 mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence, CyTOF

Unconjugated

Mouse

Adaptive Immunity, Cell Biology, Immunology

PBS with No Preservative

973

Recombinant full-length human IGA protein

Primary

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

44 kDa

IGA/515

Flow Cytometry : 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin : 0.25 - 0.5 ug/ml, Immunofluorescence : 0.5 - 1.0 ug/ml, CyTOF-ready

Monoclonal

Purified

RUO

Human

CD79a antigen, CD79A antigen (immunoglobulin-associated alpha), CD79a molecule, immunoglobulin-associated alpha, IGAB-cell antigen receptor complex-associated protein alpha chain, Ig-alpha, MB1, MB-1, MB-1 membrane glycoprotein, Membrane-bound immunoglobulin-associated protein, Surface IgM-associated protein

CD79A

IgG1 κ

Protein A or G purified

A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.